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A B S T R A C T   
There are considerable disparities between the quality of cancer care and clinical outcomes for cancer patients in 
different European countries, regions, hospitals and communities. These have persisted despite the introduction 
of many European and National Cancer Plans, an extensive portfolio of clinical guidelines and the existence of 
evidence based guidelines for the good practice in planning cancer healthcare systems. We describe the European 
Code of Cancer Practice which is a citizen and patient-centred accessible widely disseminated statement of the 
core requirements for good clinical cancer practice. The Code sets out 10 key overarching Rights of what a 
patient should expect from their healthcare system each supported by a plain language explanation. The Rights 
highlight the importance of equal access to affordable and optimal cancer care, good quality information about 
an individual patient’s disease and treatment and about the quality and outcomes of the cancer service they will 
use. Specialised multidisciplinary cancer care teams, shared decision-making, research and innovation, a focus 
on quality of life, the integration of supportive and palliative care within oncology are all emphasised. There is a 
need for a systematic approach to supporting cancer survivors with a survivorship care plan including their 
rehabilitation, reintegration into society and return to work where appropriate without discrimination. 
The Code has been co-produced by a team of cancer patients, patient advocates and cancer professionals to 
bridge the gap between clinical guidelines, healthcare policies and patients’ everyday experience. It is robustly 
evidence-based and supported by a comprehensive review of the medical literature and evidence for good clinical 
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practice. The Code is strongly endorsed by Europe’s professional and patient cancer organisations and the Eu-
ropean Commission.   
1. Background 
New knowledge of biology, detection, treatment and patient care has 
resulted in radical improvements in outcomes for many patients with 
cancer, alongside an enhanced patient experience and better quality-of- 
life (QoL). Over half of all patients with cancer who receive state-of-the- 
art diagnosis and treatment can expect long-term survival and good QoL 
beyond 10 years after their diagnosis; for most of these people, the 
outcome is a cure of their disease. However, for certain cancers, notably 
brain tumours, oesophageal, pancreatic, liver and lung cancers, progress 
remains limited and prognoses are generally poor. Cancer and the pro-
vision of cancer care still places a significant burden on Europe’s pa-
tients, citizens and economies. As the European population ages and if 
lifestyle-associated cancer risks (eg smoking, obesity) are not 
adequately addressed, then in many European countries more than half 
of the population will develop a cancer at some time during their lives 
Fig. 1. The European Code of Cancer Practice.  
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[1–23]. 
The European Code of Cancer Practice (“The Code”) [1], (Fig. 1) is a 
citizen and patient-centred accessible, widely disseminated statement of 
the core requirements for good clinical cancer practice. The Code sets 
out a series of 10 key overarching rights, signposting what all patients 
(paediatric, adolescent and adult) should expect from their health sys-
tem at all stages of their cancer journey, in order for them to achieve the 
best possible outcomes. It has its origins in the European Cancer Patient 
Bill of Rights [2–4]. It is an empowerment tool and a resource to ensure 
the best available care is delivered for European citizens and patients. 
The Code has been systematically co-produced by a team of cancer pa-
tients, cancer professionals and patient advocates to “bridge the gap” 
between policy, clinical guidelines and the everyday experience of pa-
tients and carers. 
Each of the 10 overarching rights is linked to three questions that a 
patient (or for paediatric patients their parent/guardian) may choose to 
ask their healthcare professionals (Fig. 2). Each right is supported by a 
short Explanation (Appendix A) and by a review indicating the best 
available medical literature, evidence-based guidelines and research 
evidence upon which the recommendations of the Code are based [1]. 
These include the Essential Requirements for Quality Cancer Care 
(ERQCC) series developed by the European Cancer Organisation(ECO) 
[24–31]. The whole programme of advocacy and guidance tools is 
designed to be of value for people with cancer, people at risk of cancer, 
carers, parents/guardians, patient advocates, educators and healthcare 
professionals and their trainees and may be found on the ECO website 
[1]. Timely diagnosis and treatment, good primary care and diagnostic 
capacity are vital; cancer prevention and screening are excellent ways to 
reduce deaths from certain cancer types [21–33]. 
This paper describes the Code, the scale of the challenge, the vision of 
what may be achieved and the meaning of good practice in clinical 
cancer care, coupled with the next steps for implementation and eval-
uation. The partnership between patients, advocates and professionals is 
essential. Research and innovation have a key role. 
1.1. The challenges and disparities faced by European cancer patients and 
health systems 
The increasing complexity of cancer diagnostics and treatment, the 
spiraling costs of healthcare and the ageing population all create sig-
nificant pressures on healthcare services; these challenges are met un-
equally across Europe [2–23]. Future healthcare may become confusing 
and unsatisfactory to patients and costs may make it difficult to provide 
sufficient time for the skilled health professionals required to engage 
with patients. Therefore, alongside the provision of excellent profes-
sional cancer care, empowered and informed patients can make a sub-
stantial contribution to ensure good practice and quality assurance. 
While Europe delivers high-quality cancer care and globally- 
Fig. 2. Questions that patients may ask in their consultations about the 10 
Rights in the European Code of Cancer Practice (from Reference [1]. 
Table 1 
Avoidable deaths in 2010 in EU: two different survival improvement scenarios 











Avoidable deaths when country-specific survival is raised to the top quartile of the EU 
3426 13,659 5206 9620 108,372 
Avoidable deaths when country-specific survival is raised to the median of the EU 
1321 6815 2476 5926 50,607 
The top panel shows the impact on cancer survival in the EU of raising the 
outcomes of all cancer patients to match those that are already achieved in the 
top 25 % of countries, which are making use of most of the known good cancer 
practices. In the lower panel, the impact is shown of raising the survival of all 
European patients up to the median average for EU countries - perhaps a more 
readily achievable goal. The study indicated that 50,000–100,000 additional 
people each year could survive their cancer diagnosis, if good practices were 
comprehensively implemented across EU countries [44]. 
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recognised cancer research, there are significant disparities within and 
between European nations, regions, hospitals and communities. There 
are disparities in: accessing information; accessing optimal treatment 
with all treatment modalities and optimal outcomes; being treated by 
networked, multidisciplinary cancer care teams; ensuring good com-
munications and appropriate shared decision-making; integrating can-
cer research and innovative cancer care; ensuring the best QoL for 
patients on treatment and thereafter; integrating palliative care and 
supporting cancer survivors [2–23,34–40]. Disparities between the 
quality and outcomes of cancer care between countries, regions, hos-
pitals and communities may reflect variation in the provision and uptake 
of good clinical cancer practice, but may also be influenced by socio-
economic, cultural and geographical factors [10,17,41–43]. Table 1 
shows the potential impact of implementing existing good practices in 
cancer on European and national outcomes [44]. Improvements in the 
quality of care, translation of research discoveries, and promotion of 
innovation will have to be achieved within affordable and efficient 
healthcare models [2–16,45]. 
1.2. The 70:35 vision 
In countries with good clinical practice and organisation, on average 
long-term cancer survival is experienced by 60 % of patients, although 
there may be significant variation between regions, hospitals and com-
munities due in part to differences in diagnosis, including screening, and 
treatment. However, concerted and consistent action is needed to bring 
all of Europe’s cancer care up to an acceptable level and this will involve 
informing and empowering patients, providing and training professional 
staff in adequate numbers, establishing and sustaining their expertise, 
providing facilities, equipment, material including medications, infor-
mation systems, and excellent management and leadership [1–4]. 
Our aim is to reach 70 % survival on average beyond 10 years for all 
European citizens by 2035, improving both the length and the quality of 
cancer patients’ survival [4]. 
This “70:35 Vision” should be addressed by two processes 
simultaneously:  
1 Identifying, sharing and implementing good practice in cancer 
diagnosis and care through an actively managed, systematic 
approach across countries, regions, hospitals and communities. We 
envisage that this process by itself would raise long term patient 
survival from an average of ~50 % to ~60 %. 
2 More intense research and innovation in discovery, trans-
lational, clinical and health-related cancer sciences has the real 
potential for a further increment in long-term survival towards 70 %, 
whilst improving both quality of life and the patient experience. 
We need credible tools to help patients benefit from their healthcare 
system, promote good practice and a patient-centred approach. The 
Code is such a tool. 
Cancer care planning must consider trends in incidence and mor-
tality. The Swedish Institute for Health Economics [6] has comprehen-
sively described the epidemiological context for good cancer control. In 
1995, the estimated number of cancer patients diagnosed in Europe was 
2.055 million; by 2018 it had increased to 3.081 million. Even correcting 
for the impact of the ageing population, in men, incidence rates for 
cancer have increased in the majority of countries; however, Iceland, 
Austria, Finland, Poland, Switzerland, Italy and Czechia have recorded 
slight decreases in men. In women, incidence rates have increased in all 
countries except Iceland [6]. Cancer deaths have also increased, from 
1.191 million in 1995 to 1.445 million in 2018, reflecting rising cancer 
incidence and the ageing population. Increasing age results in a higher 
incidence of cancer and poorer survival. However, age-standardised 
cancer mortality rates have fallen in men and in women in most Euro-
pean countries; ~5 million cancer deaths have been avoided in the 
European Union (EU) over the last three decades [6,46]. People up to the 
age of 64 years are showing improvements in cancer mortality. The 
influence of age on survival is likely to reflect patient fitness, patient and 
professional attitudes and healthcare access and is important in planning 
healthcare [6,47–49]. 
1.3. What is good clinical cancer practice? 
Good practice in the timely delivery of clinical cancer care is defined 
by service specifications and guidelines from international and national 
governmental and non-governmental organisations (Table 2). The 
ERQCC currently includes breast, prostate, oesophageal/gastric, lung 
and colorectal cancers, melanoma and sarcoma and primary care; work 
is in progress for pancreatic, ovarian cancer and glioma [24–31]. The 
European Society for Medical Oncology (ESMO) has a standard meth-
odology for producing its comprehensive portfolio of topic- and 
Table 2 
Key features of international and national specifications and guidelines for Good 
Clinical Cancer Practice [1].  
1. Patient-centred, specialised, and integrated multidisciplinary care for the timely 
delivery of the appropriate modalities of treatment (often combined), and 
supportive care:  
o Surgery [Right 1]  
o Radiotherapy [Right 1]  
o Chemotherapy [Right 1]  
o Biological and immunological therapy [Rights1 and 6]  
o Psychosocial care [Rights 5 and 7]  
o Palliative care at all stages [Right 8] 
2. Prompt delivery of treatment as soon after diagnosis as possible 
3. A wide range of professional groups in the planning and delivery of cancer care 
(Right 4) 
4. Attention to all age groups, including those with age-specific requirements 
including children, adolescents and young adults, and older cancer patients [Right 
1] 
5. A focus on patient centred outcomes including Quality of Life using Patient 
Reported Outcome measures [Right7] 
6. Good communication between patients and healthcare professionals about the 
patient’s diagnosis and treatment and the quality and outcomes of the care in a 
cancer service [Rights 2, 3 and 5] 
7. Well organised care integrated across a region as a network to deliver care as near to 
a patient’s home as is safe and feasible, supported by good information systems 
[Right4] 
8. Research and innovation as a core part of the work of the cancer care team [Right 6] 
9. Survivorship planning, rehabilitation and support for reintegration into family, 
social and working lives [Rights9 and 10] 
10. An active programme of oncology education [Rights 1− 10]  
Fig. 3. Patient-centred cancer care. “The development of cancer services 
should be patient-centred and should take account of patients, families and 
carers’ views and preferences as well as those professionals involved in cancer 
care. Individual’s perceptions of their needs may differ from those of the pro-
fessional” [71]. Good communication between professionals and patients is 
especially important. Fig. 3 is adapted from Abrahams et al [70]. 
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disease-specific clinical guidelines [50]. The European Commission has 
supported Member State Joint Actions against cancer, the European 
Partnership for Action Against Cancer (EPAAC) and the Cancer Control 
Joint Action (CanCon) which have already reported their results, while 
the Innovative Partnership for Action Against Cancer (iPAAC) is in 
progress. These initiatives provide frameworks for action to improve 
cancer outcomes [5,7,8]. European and national cancer societies, lea-
gues and organisations promote good cancer practice individually and 
as part of collective European anti-cancer efforts [50–69]. We summa-
rise the key features of good clinical cancer practice in Fig. 3 [70,71], 
Table 2 and in the Code’s Rights 1− 10 below. 
Currently, European countries’ cancer care and cancer services are 
organised in different ways, reflecting history, population, culture, 
health system structure and resources. In most systems, there is room for 
improvement, despite the existence of National Cancer Control Plans 
(NCCPs) in most European countries [17]. Expertise is often centralised 
into cancer centres which may be a part of a main general hospital or are 
separate institutions [72–74]. The Organisation of European Cancer 
Institutes (OECI), in its voluntary accreditation procedure [74], lays 
emphasis on a wide range of elements, including infrastructure for 
cancer care, human resources, clinical care activities, research activities, 
education and institutional structure. The OECI standards, which 
include academic and research activities and credentials, are an 
important part of Europe’s cancer care activities and frequently provide 
beacons of excellence, which can inform care in other facilities within 
different European countries and regions. These standards cover and 
reinforce all 10 of the overarching rights of the Code, to which 
accredited cancer centres should comply [74–76]. 
For good clinical cancer practice, adequate numbers of highly 
trained professional multidisciplinary teams, appropriate facilities and 
equipment to provide inpatient and outpatient diagnostics, treatment 
and follow-up are essential [see Right 1 and 4] [1–31,50–69,72–76]. In 
order to develop and sustain their expertise, teams and institutions need 
to perform a substantial volume of work. Delivering complex care - 
especially for patients with rare or advanced cancers and some complex 
“high technology “treatments - may require centralisation of services 
with a specialised team in a limited number of hospitals. However, much 
cancer care can be delivered close to a patient’s home, including some 
diagnostics, follow-up and relatively straightforward cancer treatments. 
The literature on the relationship between the volumes of clinical ac-
tivity (patient or procedure numbers) required to establish and sustain 
good clinical practice and outcomes is extensive [77–85]. The degree of 
centralisation varies between different cancers and treatments [24, 
2–31] and care close to home, together with assuring equity of access, 
and consistency of good practice, is facilitated by high-performing 
cancer care networks [86–91] (ECCP 4). 
Good practice requires constant review, updating and continuing 
education and will evolve substantially over time. Currently, research 
and innovation, often using established scientific concepts and tech-
nologies, are enhancing good clinical cancer practice continuously 
(Table 3) [92–103]. Collaborative research organisations including the 
European Organisation for Research and Treatment of Cancer (EORTC, 
63), Cancer Core Europe [104] and the European Academy of Cancer 
Sciences [69] have a key role to achieve the ambitious goals of the Code. 
1.4. Patient involvement, engagement and empowerment 
Patient involvement, engagement and empowerment can improve 
patient satisfaction, the quality of care provided, and patient outcomes 
[105]. ‘Engagement’ expresses the commitment of healthcare pro-
fessionals to intentionally and meaningfully include patients in discus-
sions and decisions about their care. ‘Empowerment’ is a wider concept 
that encompasses commitment and action by patients who are 
self-derived and self-driven and may occur outside the interactions with 
healthcare professionals. The European Patients’ Forum (EPF) has 
developed a Charter on Patient Empowerment [106]. Systematic re-
views of scales that measure empowerment exist [107]. The OECI has 38 
quality standards on patient involvement and empowerment which 
accredited cancer centres should comply with, ranging from co-creation 
of services, to shared decision-making [108]. Patient involvement, 
engagement and empowerment are ethical imperatives and an 
evidence-based choice, resulting in better psychosocial and economic 
Table 3 
Research and Innovation which is improving cancer practice (from references 
[92–104].  
1. Advances in understanding the cell and molecular biology of cancer and cancer 
genetics which characterise the hallmarks of cancer, underpin advances in cancer 
pharmacology and drug development, immunology and microbiology, 
immunotherapy and vaccines [92,93,94]. 
2. Precision oncology allows clinicians and patients to choose the right treatment at 
the right time [95]. 
3. New radiotherapy technologies allow ever more targeted treatment approaches [97, 
98,99,100]. 
4. Surgical advances include robotics, minimally invasive technologies, imaging 
enabled approaches, and oncoplastic reconstructive surgery [34,55]. 
5. Interventional radiology/oncology are providing means of destroying localised 
cancers using heat or cold [101]. 
6. Physical Sciences are delivering new tools to improve diagnostics and all treatment 
modalities [102]. 
7. Health Informatics and Artificial Intelligence/Machine Learning can inform service 
planning and delivery [13]. 
8. Applied health research provides insights into the effective organisation of 
healthcare [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23].  
Fig. 4. 5-year age-standardized net survival rates for colon cancer in European adult patients (15-99 years), 1995-2014. Hatched bars are based on regional data or 
neighbouring countries. Survival ranged from 51 % in Croatia to 68 % in Belgium and Iceland. Over half of European countries are now reporting survivorship at five 
years at or above 60 % (from reference [6] with permission). 
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outcomes [105–109]. 
The Patient Advisory Committee of the European Cancer Organisa-
tion, established in 2008, provides a setting for 20 European patient 
organisations and bodies involved in patient care, to work together with 
ECO Member Societies and provide their direct insight into the chal-
lenges faced by cancer patients and inequalities in cancer care [51]. 
ESMO [50], in collaboration with the European Cancer Patient Coalition 
(ECPC) [52] produce ESMO Cancer Patient Guides. European cancer 
patient advocacy organisations and the Workgroup of European Cancer 
Patient Advocacy Networks (WECAN), co-produce a wide range of 
policy and strategy papers. 
2. The European Code of Cancer Practice 
The European Cancer Patient’s Bill of Rights [1–4], which was 
awarded the 2018 European Health Award at Gastein [110] was the 
forerunner of the Code. The next step was to turn the concepts of the Bill 
of Rights into a Code and this was derived by a process of systematic 
Fig. 5. 5-year age-standardized net survival rates for breast cancer in female European adult patients (15-99 years), 1995-2014. Hatched bars are based on regional 
data or neighbouring countries. Improvements are apparent, with well over half of countries reporting survivorship of over 80 % at five years, but with considerable 
diversity (from reference [6] with permission). 
Fig. 6. Disability adjusted life years (DALYs) lost due to cancer 
per 1000 inhabitants in 31 European countries, 2000 & 2016 
[6]. There is great diversity between countries. The biggest 
reductions in cancer related DALYs lost have been seen in 
Czechia, Luxembourg, Denmark and Norway; the biggest in-
creases have been seen in Bulgaria and Romania. The cancers 
which cause the greatest disease burden measured in DALYs 
are lung cancer, CRC and breast cancer, with pancreatic and 
prostate cancer increasingly contributing to the cancer burden 
(from reference 6 with permission).   
Fig. 7. Cost of cancer medicines per capita in 31 European countries at 2018 price levels and exchange rates, 2008 & 2018 (from reference [6] with permission). 
Hatched bars are based on regional data or neighbouring countries. There has been a substantial increase in most countries and considerable variation between 
countries. Highest expenditures are in Austria, Switzerland, Germany, Belgium and Denmark. 
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co-production, with a core steering group - two patient advocates and 
two cancer professionals, reflecting our co-production values. They 
initially consulted with a group of 65 people with equal numbers of 
patient advocates and professionals [4]. The draft Code was refined by a 
smaller group of 14 patient advocates and professionals who formulated 
the patient Questions and drafted Explanations of each of the 10 rights 
captured in the Code. The whole programme was then reviewed by the 
member organisations of the European Cancer Organisation, the Euro-
pean Cancer Organisation Board and Patient Advisory Committee. The 
final version was checked for compatibility with existing systematically 
prepared guidelines and service specifications. 
The ten rights in the Code are: 
1) You have a right to equal access to affordable and optimal 
available cancer care, including the right to a second opinion. 
Central to the European Code of Cancer Practice is the right of pa-
tients to access affordable and optimal available cancer care [1], (Fig. 1), 
(Appendix A). However, there is compelling evidence that not all 
countries, regions, hospitals and communities currently provide access 
to good clinical cancer practice, reflected in their less than optimal 
cancer patient survival [2–23,34–44]. The Comparator Report [6] gives 
net survival in a variety of cancers and countries. Figs. 4 and 5 show 
five-year age standardised net survival rates for colon cancer and breast 
cancer. There is clear evidence of improvement in survival for both, but 
with considerable variation in outcomes between countries. 
The World Health Organization (WHO) has adopted a comprehen-
sive measure of disease burden [6,111], Disability-Adjusted Life Years 
(DALYs). Fig. 6 shows the DALYs lost due to cancer in 31 European 
countries [6]. Studies are beginning to identify variations between Eu-
ropean countries in the efficiency of cancer care. Increasing expenditure 
is usually associated with improvements in survival. However, in ana-
lysing the efficiency of cancer care delivery there is considerable vari-
ation between countries, which is not explained by expenditure alone [6, 
45]. 
There is unequal deployment of cancer treatments across Europe [5, 
6]. Fig. 7 shows expenditure per head of population on cancer medicines 
in 2008 and 2018 [6]. Fig. 8 shows that access to the best surgical care 
varies greatly in different European countries [34,55,112–115]. 
Considerable inequality exists in the utilisation of radiotherapy [36–38, 
49,56,116,117], (Fig. 9). Monitoring variations in access to good quality 
care and its influence on outcomes, as is demonstrated by the work of the 
European Registry of Cancer Care, is a vital part of ensuring good 
practice for cancer patients [118]. 
2) You have a right to information about your own disease and 
treatment from your medical team and other reliable sources, 
including patient and professional organisations. 
Excellence in patient-centred care requires informed decision- 
making following good communication and provision of good-quality 
information [5,9,119,120] (Fig. 3), (Appendix A). Communication 
Fig. 8. The proportion of breast cancer (T1N0M0) patients receiving standard 
good clinical cancer practice with Breast Conserving Surgery and Radiotherapy 
in different European Countries. The results of a EUROCARE-3 study show the 
uptake of standard good clinical cancer practice in the surgery of women with 
localised, small, lymph node negative breast cancer ranged from 78 % to 
9% [112]. 
Fig. 9. Radiotherapy uptake in Europe. The figure shows actual radiotherapy utilisation as proportion of optimal evidence-based utilisation. In general, diversity is 
seen in the uptake of evidence based radiotherapy, the equipment available per citizen and per cancer patient, the optimal utilisation of radiotherapy treatments and 
considerable variation in radiotherapy staffing numbers [35]. 
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skills training including breaking bad news and explaining complex 
treatments and clinical trials, are now an important part of undergrad-
uate education in healthcare and of continuing professional education in 
all oncology disciplines [121,122]. Good communication from health-
care professionals to patients and their families begins with a courteous 
introduction explaining who you are and what you are there to do, and 
that you will tell them the truth. Professionals should listen carefully to 
patients’ history, problems and background. A good consultation will 
usually involve as much listening as talking. An organised approach to 
communication is helpful for both patients and professionals. 
The Association of European Cancer Leagues (ECL) Patient Support 
Working Group [123] has produced a structured guide on how a patient 
may prepare for a medical consultation (Table 4). A well-structured 
example to aid cancer professionals to communicate well is the 
DREAM five-component protocol [119]. Table 5 uses the DREAM 
outline to summarise the features of an approach to good communica-
tion with cancer patients. 
3) You have a right to information about the quality and safety of 
care, the level of expertise and the outcomes achieved for your type of 
cancer in the cancer care service where you are being treated. 
Cancer patients and professionals need high-quality clinical data 
indicating the outcomes for patients undergoing care at cancer centres 
and hospitals at a national, regional and local level. Patients need the 
data to judge whether the service providing their own care is working 
effectively; healthcare professionals need the data to audit their results 
and determine how they can improve their practice; healthcare man-
agers need the data to assess the value of the service they provide; 
policymakers need good data to underpin policy initiatives. Easy-to-use 
and interoperable IT systems and data managers are paramount [5,9, 
124]. These are not always found in hospitals or healthcare systems. 
The provision of information to support cancer patients in their 
choice of centres is principally at a national level. A patient’s individual 
service should be able to provide a point of access to this information. 
For example, the Italian Oncoguida [125] “provides detailed, 
patient-oriented information on Italian hospitals and cancer centres providing 
cancer care, including volume of surgeries performed per tumour site, avail-
ability of psychological and physical rehabilitation services and contact de-
tails of patient associations involved at the hospital level.” [125,126]. In the 
UK, “My NHS” website [127–129] can be accessed by a patient to 
examine the performance, staffing, clinical outcomes and treatment 
delivery of their cancer service. 
4) You have a right to receive care from a specialised multidisci-
plinary team, ideally as part of a cancer care network. 
Specialised multidisciplinary team (MDT) cancer care has been rec-
ommended by cancer organisations, governments, learned societies and 
patient advocacy organisations since the 1990s [71,130–133]. A key 
recommendation of CanCon is to “Ensure equitable access to timely, high 
quality and multidisciplinary cancer care”. However, it must be delivered 
efficiently and affordably, with the best possible impact and the optimal 
infrastructure and informatics [133], (Table 6). The evidence on the 
impact of MDTs is extensive but uneven. Kesson et al. [134] studied the 
impact of MDTs in Glasgow on breast cancer patient survival, finding 
improved survival and reduced variation in care. MDTs must be kept 
efficient to justify their cost. Human factors such as unequal participa-
tion, varying quality of leadership, inconsistent communication, and 
decision-making fatigue can all reduce the quality of the decisions 
[135–137]. The ERQCC [24–31] emphasises the varied impact of MDTs 
between different cancer types. Despite the importance of MDTs in all 
cancer types, the actual constitution of the MDT may vary among 
different cancer types. The OECI 27 quality standards for multidisci-
plinary teams are designed to reduce unhelpful inconsistencies in the 
way teams operate, to enable effectiveness of discussion and process, 
and to stimulate a culture of learning and continuous improvement in 
Table 4 
European Association of Cancer Leagues (ECL) advice to patients preparing for a 
consultation (adapted from reference [123].  
1. Before the consultation: Ask a relative, friend, partner, carer or advocate to 
accompany you to your appointments, make a list of questions you would like an 
answer to, make a list of all medicines and pills you take, including vitamins and 
supplements, write down details of your symptoms, including when they started and 
what makes them better or worse, do not be afraid to ask your doctors to repeat and/ 
or clarify anything they say, ask if you can record consultations on your smartphone. 
2. Before you leave: Check you have asked all the questions on your list, know what 
the next steps are, ask who you can contact if you have any problems or further 
questions, ask for reliable sources of information about your disease and treatment 
options. 
3. After the consultation: Keep all your notes safe - in case you ever need to refer to 
them, book dates for the next appointments in your diary, discuss the results of the 
consultation with your loved ones.  
Table 5 
The DREAM interview: key components and skills needed by cancer pro-
fessionals conducting consultations (reproduced with permission from reference 
[119).  
Data Collecting accurate data, i.e. taking a clear medical history needs 
knowledge about appropriate use of open, focused-open and closed 
questions, and avoidance of leading and multiple questions 
Set up the interview carefully and allow adequate time; include a 
patient’s spouse, partner or friend who will help their recall; ensure 
you know the patient’s pre-existing knowledge – their ‘starting point’ 
Relationship Establishing a relationship or rapport, i.e. learning more about the 
patient’s worries and concerns and making the patient feel 
comfortable by giving and asking information, not interrupting too 
much or looking at notes 
This needs awareness of verbal and non-verbal communication and 
the ability to engage in active listening 
Empathy Being empathic, i.e. responding appropriately to patient-led cues 
Acknowledge the burden of disease and treatment 
Advice Giving advice, i.e. explaining the logic and rationale for treatment, 
and putting complex information into layperson’s terms 
This needs the ability to structure information into manageable 
chunks, to summarise and to constantly check understanding 
Encourage note taking or recordings: it is good practice to give 
patients brief notes of the main points at the end of the interview 
(these may be made by an accompanying healthcare professional) 
Motivation Providing motivation, i.e. ensuring that the patient understands the 
true therapeutic intent of treatment and feels motivated to embark on 
therapy with the likelihood of achieving realistic goals 
This needs use of unambiguous language and the ability to focus the 
patient on goals such as improving QOL  
Table 6 
The impacts of Multidisciplinary Team (MDT) working (adapted from reference 
[133].  
1. Treatment and care being considered by professionals with specialist knowledge 
and skills in the relevant aspects of that cancer type. 
2. Patients being offered the opportunity to be entered into high-quality and relevant 
clinical trials. 
3. Patients being assessed and offered the level of information and support that they 
need to cope with their condition. 
4. Continuity of care, even when different aspects of care are delivered by different 
individuals or providers. The information provided by different team members must 
be consistent and clearly recorded, such that it can be readily transferred to other 
teams in hospitals or the community which may contribute to the patient’s care. 
5. Good communication among primary, secondary, and tertiary care. 
6. Optimal data collection, for the benefit of the individual patient and for the 
purposes of audit and research. 
7. Improved equality of outcomes as a result of better understanding and awareness of 
patients’ characteristics and through reflective practice. 
8. Adherence to national and local clinical guidelines. 
9. Promotion of good working relationships between staff, thereby enhancing their job 
satisfaction, mental health and QoL. 
10. Opportunities for education/professional development of team members 
(implicitly through the inclusion of junior team members and explicitly when 
meetings are used to devise and agree upon new protocols and ways of working). 
11. Optimization of resources – effective MDT working should result in more efficient 
use of time, which should contribute to more efficient use of resources more 
generally.  
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the team [74]. 
Integrated Care within Cancer Networks is recommended by EPAAC 
and CanCon as a key requirement for optimal quality cancer care [5,7, 
71,86,132]. Specialised MDTs require a substantial team and infra-
structure and a sufficient volume of activity to maintain high quality 
[77–85]. Integrated cancer care in Comprehensive Cancer Care Net-
works (CCCN, Table 7), can improve the quality of care and outcomes. 
Networks have a key role in delivery of care for people with rare cancers 
for whom they may often need to be extended internationally [138]. 
Cancer networks across Europe - for example those in France, Spain and 
the UK - have considerable differences in governance, management 
structures and degree of network maturity. [5,7,71,86–91]. Prades et al. 
[86] noted “The cancer network model, epitomised by the UK experience, 
has shown great potential to improve health outcomes by making better use of 
scarce clinical expertise, enhancing service coordination, and increasing pa-
tient access to services and clinical trials” [71,86–91]. This has recently 
been supported by Australasian findings [139,140]. There are currently 
no consistent frameworks for evaluating the effectiveness of cancer care 
networks, although OECI is in the course of piloting a specific set of 
network standards to ensure equity of access to high quality care for 
patients, wherever they live. 
5) You have a right to participate in Shared Decision-Making with 
your healthcare team about all aspects of your treatment and care. 
Decision-making in a clinical consultation may be passive in which 
the doctor takes the decision, active in which the patient receives in-
formation and then takes the final decision or there may be a shared or 
collaborative approach in which a doctor recommends a treatment 
taking account of the patient’s views [119]. It must always be kept in 
mind that unwell and anxious patients may find it difficult to decide 
their treatment preferences. Shared decision-making is widely preferred 
but can be challenging, especially if a clinician or MDT have a strong 
view. A treatment preference may be right for the average patient but 
not right for an individual. Shared decision-making should result in less 
regret about the decisions taken. It should aid coping, resulting in better 
treatment compliance, which should improve QoL and survival. Cancer 
professionals require training and experience in communication to elicit 
truly educated/informed consent [119,141]. In a large US study [142], 
high levels of shared control were preferred by patients with more pa-
tient control observed in chemotherapy decisions and more physician 
control in surgery and radiation decisions. Ring et al. [143] found in 
women over 70 years with breast cancer that 58.5 % preferred shared 
decision-making. Wilding et al. [144] surveyed 17,193 men after pros-
tate cancer treatment and found that regret about the treatment 
decisions taken was more common when patients reported that their 
views had not been taken into account. Decisions may involve opinions 
from families, friends, and other patients and - increasingly in modern 
practice - internet sources. 
Decision aid tools providing clear, comprehensible information in an 
appropriate format will help shared decision-making [119]. For 
example, the decisions faced by breast cancer patients include difficult 
options for the extent of surgery and modalities of adjuvant therapy 
[145]. An example of a decision aid tool is the PREDICT-UK online tool 
which helps patients and clinicians see how different systemic treat-
ments for early breast cancer might improve survival after surgery 
[146]. 
A Cochrane Systematic Review was applied to studies which had 
sought to clarify the impact on patients of the treatment and screening 
options which were presented to them. The Review considered 55 
clinical trials across the wide range of treatment and screening options. 
Its conclusion was that where patients had a greater participation in 
decision making, then they had greater comfort/satisfaction with the 
decisions taken [147]. 
6) You have a right to be informed about ongoing research relevant 
to you, and your ability and eligibility to participate in research. 
To bring new cancer discoveries into clinical practice requires 
concerted basic research, research to translate the findings towards 
clinical use and clinical research. The transition from basic science and 
innovation to early phase clinical trials is often referred to as the “first 
translational gap”. Second, an innovation whose concept is proved in 
early phase clinical trials, must be demonstrated in large scale late phase 
trials and then disseminated across a whole healthcare system, the 
“second translational gap” [148]. 
Research brings benefits to patients both through the implementa-
tion of its results and its influence on the quality of clinical cancer care. 
We have summarised those areas of research which are currently 
improving or likely to improve cancer practice in the foreseeable future 
in Table 3 [92–103]. While patients must be absolutely free to choose 
whether they wish to be individually involved or continue to be involved 
in research, it is essential that they have the right to be informed about 
research options and the research activities of their cancer care teams. 
Clinical trials determine if a new treatment is better than or equiv-
alent to existing treatments or diagnostic strategies. When trials are 
positive, then this should help improve patient outcomes. Even when 
new approaches are shown to be equivalent to existing approaches, this 
Table 7 
The CanCon definition of a Comprehensive Cancer Care Network (CCCN) (from 
reference [132] with permission).  
A CCCN consists of multiple units belonging to different institutions dedicated to 
research, prevention, diagnosis, treatment, follow-up, supportive and palliative 
care, and rehabilitation for the benefit of cancer patients and cancer survivors. 
These units interact and have a formal agreement to work together in a programmatic 
and structured way with common governance, in order to pursue their goals more 
effectively and efficiently through collective synergies. 
Within the CCCN the care of patients is the responsibility of inter-professional teams 
that are multidisciplinary and tumour-specific. Each team or tumour management 
group works together for the benefit of patients with that particular type of tumour. 
Within the CCCN all units work together and adopt uniform standards of care for 
cancer-specific pathways that are binding for the entire network. 
The CCCN promotes a uniform system of quality assurance, and a unified informatics 
system for optimal exchange of information. 
The objective of a CCCN is to provide comprehensive cancer care to all the people 
living in a certain geographic area, thus pursuing equality and the improvement of 
outcomes and quality. 
The word unit is used to designate any component of a CCCN, whether an entire 
pre-existing institution or part of an institution. For example, a unit might be an 
entire cancer centre, an oncology department of a general hospital or a chil-
dren’s hospital, a mammography facility, a pathology laboratory carrying out 
mutation analysis, or a hospice [5]. 
Fig. 10. Cumulative life-years gained through 2015 by SWOG clinical trials. 
The cumulative life years gained through the implementation of positive RCTs 
is plotted for each trial through to 2015. The colour coded areas represent 
cumulative life-years for each of the 23 studies evaluated. For each colour, the 
cumulative life years saved are plotted 1970–2015. The impact of each indi-
vidual study is added with a new coloured segment so that the total cumulative, 
additive impact of all 23 studies combined is shown with the contribution of 
each study shown by a separate colour. Four studies are shown to contribute 
two thirds of the life years saved. Reproduced with permission [149]. 
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can still result in better care, if the new approach is less toxic, less 
inconvenient or cheaper. The USA Southwest Oncology Group (SWOG) 
[149] in its 60-year history conducted 23 positive RCTs which estab-
lished new standards for care. They estimated population life-years 
gained through 2015 by mapping the effect of the new treatments 
onto the US cancer population (Fig. 10). 3.34 million (95 % confidence 
limit, 2.39–4.15 million) life-years were gained at a cost of $125 per 
life-year gained, an impressive return on investment in lives saved for 
the money spent [149]. However, evidence from clinical trials may 
diffuse slowly into daily clinical practice. There may be a number of 
reasons for this, such as poor knowledge diffusion, insufficient re-
sources, and inadequate reimbursement systems [37,38,150]. 
The claim that patients in clinical trials have better outcomes than 
patients with the same disease in the same institutions who are not in 
trials is not supported by systematic reviews [151]. However, a hospital 
which participates actively in research by entering patients into trials in 
large numbers, delivers better outcomes than a research-inactive hos-
pital [152–157]. Research participation might stimulate the consider-
ation of new evidence, introduce improved cancer treatments and 
equipment, while the interaction between researchers and clinicians can 
have an impact on all treated patients with the disease in that hospital. 
Systematic reviews support the positive influence of research partici-
pation on the processes of care delivery [152]. Clinical trial activity also 
correlates with improved care quality and patient satisfaction in hos-
pitals [152–156]. Relatively small studies all highlight positive associ-
ations between research participation and patient survival (reviewed in 
155). A large study in over 200,000 patients with colorectal cancer over 
10 years in the English NHS showed that the provision of research 
infrastructure improved the recruitment, speed, quality and integration 
of clinical cancer research; in a multivariable case mix adjusted analysis 
there was a strong association between research participation and pa-
tient survival [157]. A review and literature meta-analysis supports the 
conclusion that research-intensive hospitals have substantially better 
outcomes, independently of their size, inferring a causal relationship 
[155]. 
7) You have a right to discuss with your healthcare team your 
priorities and preferences to achieve the best possible quality-of-life. 
The increasing emphasis on QoL comes from greater awareness of the 
needs of patients and also from an increasing ability to measure those 
needs using Patient Reported Outcome Measures (PROMs). The first 
PROMs used in oncology were health-related quality of life question-
naires measuring physical symptoms, psychological distress, the impact 
on daily functioning and patient perceptions of their QoL and well-being 
[158,159]. PROMs such as the Distress Thermometer and the Hospital 
Anxiety and Depression Scale [160,161] were used as screening tools, 
included in oncology trials supporting patient-centred clinical conclu-
sions. Digital data collection and electronic medical records allowed the 
collection of PROMs in daily oncology practice to screen for symptoms 
or psychological distress, monitoring symptoms and treatment response. 
PROMs can promote patient-centred care by highlighting concerns and 
prompting discussions; identifying psychological and physical problems; 
facilitating patient-doctor communication; engaging patients in shared 
decision-making; improving symptom control, patient well-being and 
patient satisfaction; improving patient survival and reducing care costs 
[158,162–171]. 
International organisations such as the International Society for 
Quality of Life Research (ISOQOL) and the Quality of Life Group of the 
EORTC have developed practical guidelines on how to incorporate 
PROMs in clinical practice [158,172,173]. The Patient-Centred 
Outcome Research Institute (PCORI) of the USA National Institutes of 
Health has published a “Users’ Guide to Integrating Patient-Reported 
Outcomes in Electronic Health Records” [174,175]. PROMs may be 
used to survey large populations to evaluate key healthcare outcomes 
such as the QoL of cancer survivors [176]. The international consortium 
SISAQOL (“Setting International Standards in Analyzing 
Patient-Reported Outcomes and Quality of Life Endpoints Data”) aims to 
improve the analysis and presentation of QoL data [177]. Guidance 
written by leaders of cancer patient advocacy organisations on how to 
include the patient voice in PROMs has been produced [178]. 
‘Psychological distress’ including worry, intrusive thoughts, low 
mood, poor concentration, sleep difficulties and appetite changes, below 
the threshold for a diagnosable psychiatric condition, are common in 
cancer patients. The prevalence of mental disorder has been shown to be 
between 30 % and 40 %, whereas major depressive illness is found in 
from 8% to ~25 % of people with cancer, and anxiety disorder in about 
25 % [179]. These problems may not be detected consistently by 
oncology teams [180] and patients should be screened for psychological 
morbidity at key points in their disease trajectory [179,180]. Psycho-
logical support should be provided in a stepped-care approach which 
addresses the needs of patients with few psychological needs, through to 
those needing specific intervention [181], (Table 8). 
The social impact of cancer may be considerable, not only at the time 
of diagnosis, when immediate readjustments may have to be made, but 
also possibly over many years following diagnosis. Early and late side 
effects of treatment result in chronic disability and restrictions in per-
forming daily activities. Patients at all stages of disease report problems 
in all domains of life: in the home, with support services, aids and ad-
aptations, with finances and insurance, employment including the self- 
employed, legal aspects with family affairs and wills, with relation-
ships, sexuality and body image, recreation, holidays and with housing 
and transportation [182]. Although most patients are able to cope, a 
significant minority struggle. In 17,000 CRC patients, 15 % reported 
levels of social challenges which if found in clinical practice would have 
warranted some form of further assessment [176,182,183]. Patients 
with multiple social concerns or difficulties have been shown to be more 
likely to exhibit clinically significant anxiety or depression [182,184]. 
8) You have a right to receive optimal supportive and palliative 
care, as relevant, during any part of your cancer journey. 
Evidence clearly supports the benefits of earlier referral to palliative 
care and this should be promoted more widely as an important step to 
counter the perception that referral represents oncological failure or 
imminent death. Developing more integrated clinical practices between 
oncology and palliative care is helpful [185–187]. Early palliative care 
improves symptoms, QoL, reduces acute hospital admissions, and may 
Table 8 
Recommended model of professional psychological assessment and support 
(from reference [181].  
Level Who should provide 
it? 
What should be 
assessed? 
What is the 
intervention? 
















Use of standardised 
screening tools, e.g. the 
Distress Thermometer 
and the Hospital 
Anxiety and Depression 
Scale 













according to an explicit 
therapeutic framework 






interventions such as 
psychotherapy, 
including cognitive 
behavioural therapy  
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improve survival [188–192]. Systematic reviews and pooled analyses of 
routinely collected data have demonstrated an association between 
early palliative care intervention and an increased proportion of home 
deaths as the preferred place of death. Integrating supportive and 
palliative care into oncology can result in less hospital admissions, 
reduction in stay in hospital, fewer intensive care hospital days, lower 
costs, and increased trial recruitment [187]. However, referring all pa-
tients to specialist palliative care at diagnosis with advanced disease is 
not currently feasible in most European cancer practices. Society’s views 
on palliative care are another barrier, with misconceptions which 
include assumptions that palliative care is only for patients at the very 
end of life, and a lack of appreciation of the breadth of services provided 
[185–195]. However, some European organisations are setting a higher 
bar for earlier and more integrated intervention of specialist services, 
such as the ESMO-designated centres of oncology and palliative care, 
and the OECI quality standards, which define the optimal compositions 
of both palliative and supportive care teams, and structured referral 
processes [74,193]. 
9) You have a right to receive and discuss with your care team a 
clear, managed and achievable plan for your survivorship and 
rehabilitation. 
The substantially increasing number of cancer survivors in Europe 
led the EU Joint Action on Cancer Control (CanCon) to focus on survi-
vorship and rehabilitation as part of the European guide on quality 
improvement in comprehensive cancer control [5,196,197]. The EORTC 
and others have highlighted the importance of survivorship and 
addressing this need through research and innovation [63,198–201]. 
The European Cancer Organisation has established a Survivorship and 
Focussed Topic Network [51]. CanCon used the very inclusive definition 
of survivorship provided by the US National Coalition for Cancer Sur-
vivorship [202]: ‘the experience of living with, through and beyond a 
diagnosis of cancer’. The definition of a survivorship plan by the US 
National Cancer Institute is: ‘A detailed plan for a patient’s follow-up care 
after treatment for a disease ends” [203]. In preparing the Code, we have 
focused on the period of time after some active cancer treatment has 
been successfully finished. All divisions are quite artificial and an 
awareness of survivorship-related issues should be maintained at all 
parts of a patient’s journey [184–204]. 
In Europe during the last six years, there has been increased 
awareness of survivorship challenges faced by cancer patients leading to 
policy makers adapting the law related to financial challenges. Inno-
vative measures have been taken in France, Belgium, Luxembourg and 
the Netherlands establishing a “Right to be Forgotten” such that cancer 
patients do not face discrimination [200,201,204–206]. This may allow 
some cancer survivors to apply for insurance without having to disclose 
their history of cancer. Even when insurers know about a person’s 
cancer diagnosis - for example, based on a person’s previous insurance 
claims - they are not allowed to incorporate this information into new 
insurance policies. However, there is a need to provide equal access for 
all Europe’s cancer survivors to such legislation. Recently, the EU 
Commission has also stressed the need for a “Right to be Forgotten” [14, 
15]. 
CanCon identified the importance of a survivorship care plan for 
the follow-up of cancer survivors to overcome the many factors 
impeding good QoL [196,197], covering both medical and non-medical 
aspects of care. Models reported include the shared care model and the 
availability of specialised survivorship clinics. Evidence suggests that 
there is considerable added-value for patients and healthcare systems 
with the use of survivorship care plans, even though they are currently 
far from routinely employed [207–209]. However, for their accredited 
cancer centres, an OECI quality standard specifically requires that a 
personal survivorship care plan is discussed and agreed with each pa-
tient, covering all their requirements and available support mechanisms 
[74]. Self-management support can help patients to manage the issues 
they face as cancer survivors, as active partners, working in collabora-
tion with healthcare providers. The main messages on survivorship from 
CanCon are shown in Table 9 [196,197]. 
An increasing proportion of survivors are concerned about fertility 
issues [210–213]. Consideration of early referral to a fertility specialist 
should be incorporated into the MDT strategy. Prevalence rates of sexual 
difficulties associated with cancer and its treatment vary widely, 
depending on the diagnosis and treatment. Discussing the sexual con-
sequences of cancer is difficult for healthcare professionals and patients 
alike. Screening patients and the use of PROMs may assist busy clini-
cians. Sexual difficulties may improve over time with medical, psycho-
logical and relationship strategies [214]. 
10) You have a right to be fully reintegrated into society and pro-
tected from cancer-related stigma and discrimination, so that, in so far 
as is possible, you can return to work and a normal life. 
The physical, social and psychological challenges faced by cancer 
survivors have been summarised in Rights 7, 8 and 9. However, a crit-
ically important aspect of reintegrating into normal life for many cancer 
patients involves returning to work. The European Agency for Safety and 
Health at Work (EASHW) in 2018 reported on “Rehabilitation and re-
turn to work after cancer - instruments and practice” [215] and evalu-
ated good practice, case studies, qualitative research, and stakeholder 
views. They found that some patients had diminished work productivity 
and ability early in treatment as expected, but these consequences can 
also last years after diagnosis (Table 10). 
The Association of European Cancer Leagues [54] has identified the 
issues and potential solutions to the challenges faced by cancer patients 
at return to work [54,216]. Among all chronic conditions, cancer has by 
far the highest prevalence of work loss and reduction in work func-
tioning, with an average return to work rate of 64 % after 18 months, 
Table 9 
The main messages on cancer survivorship from the CanCon Member State Joint 
Action Against Cancer (from reference [5].  
Cancer survivors’ follow-up, late effects management and tertiary prevention needs 
should be anticipated, personalized and implemented into care pathways, with 
active participation of survivors and relatives 
Improvement is needed in early detection of patients’ needs, and their access to 
rehabilitation, psychosocial and palliative care services is required 
An integrated and multi-professional care approach is required with coordination of 
community care providers and services to implement a survivorship care plan that 
enhances patient self-management and QOL 
For child, adolescent and young adults survivors, late health and psychosocial effects 
of cancer and its treatments should be anticipated and addressed 
More research in the area of survivorship is needed to provide data on late effects, as 
well as the impact and cost-effectiveness of supportive care, rehabilitation, 
palliative and psychosocial care interventions  
Table 10 
The challenges of cancer patients Returning to Work (RTW) (from reference 
[215].  
1. The total economic loss to the European Union (EU) due to lost working days to 
cancer was estimated to be EUR 9.5 billion in 2009, not all related to unsuccessful 
RTW. 
2. When returning to work, survivors may face difficulties in balancing work and 
treatment demands, including negative attitudes or behaviours among their 
colleagues and employers. 
3. Small or medium sized companies (< 250 workers), especially smaller ones, and the 
self-employed lack resources for RTW strategies or programmes, and support for 
them is needed. 
4. Results from the modest scientific literature show that only multidisciplinary 
interventions that combine vocational counselling with patient counselling and 
physical training have increased RTW rates, although only to a small extent. 
5. Workplace accommodations are needed to provide more flexibility or a reduction in 
working time, including paid leave for healthcare appointments, adjustments to 
workload and duties, and the provision of assistance. 
6. Psycho-educational interventions, such as advising cancer survivors by telephone or 
providing information on a dedicated website are needed. 
7. A range of RTW instruments, practices, policies and interventions exist for workers 
with cancer, and these are considered essential for improving the work outcomes of 
those diagnosed with cancer.  
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and a greatly increased risk of unemployment [183,215]. Employers 
face a communication challenge with employees diagnosed with cancer 
and often do not understand the needs of the patient to return to work. 
Employees may feel guilty about time off work and be nervous about job 
security and promotion. They may fear an uncertain future, be embar-
rassed with colleagues, lack personal confidence to work efficiently and 
have financial concerns connected to their diagnosis and treatment. 
ECL (Table 11), [54,216] urges employers:  
1 Do not postpone problems associated with returning to work and 
deal with them as soon as possible.  
2 Support a good and fluid communication during the whole pathway.  
3 Be flexible on working conditions where possible. 
These solutions are aimed at advising employers and employees but 
they can provide a useful framework for planning for self-employed 
patients and their families, who will face considerable, work-related 
challenges. 
3. Discussion and next steps 
The European Code of Cancer Practice [1] provides a tool to help 
patients navigate the significant challenges they face when diagnosed 
with cancer, as well as providing cancer professionals with help in the 
development of their own patient-centred approaches to good cancer 
practice. The Code represents an invaluable aid to training patient ad-
vocates, professionals and trainees in all professions, based on the best 
available medical literature and evidence. 
In order to achieve the goals of improved cancer outcomes and QoL, 
an active programme of dissemination, implementation and evaluation 
of the Code is needed. We envisage the Code as a core resource to be 
retained and updated. However, to be fully effective it will have to be 
relevant to all countries and regions in Europe, to patients with many 
different cancer diagnoses and to all age groups. This will require its 
adjustment to be meaningful and accessible for such a wide range of 
audiences. Careful critical evaluation of the Code’s uptake, impact and 
content will be needed at a European level and also in individual 
countries, regions, hospitals and communities. Evaluation findings 
should be shared and fed back to influence the Code and its de-
velopments [217]. Currently, the Code has been translated into 25 
languages, facilitating its dissemination and deployment across Europe. 
The EU Health and Food Safety Commissioner has indicated her support 
for the wide dissemination of the Code. 
The provision of evidenced-based guidance in a format that is 
accessible to patients and professionals can directly influence individual 
consultations and help in the more consistent introduction of good 
practice and improve outcomes. The prestigious award given to the 
programme [98] and the recent support and formal endorsement of the 
current EU Health Commissioner and her colleagues add to the Code’s 
credibility [1]. However, we envisage that the use of the Code will 
improve practice and outcomes through a process of iteration between 
informed patients asking evidence-based questions and the clinicians 
and policymakers who are thereby consistently challenged to improve 
their own practice and policies and to influence their colleagues and 
trainees [218]. The Code should also influence the further development 
of quality standards and service specifications in hospitals and other 
settings. 
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Appendix A 
THE EUROPEAN CODE OF CANCER PRACTICE: Explanations of the 
Rights of the European Code of Cancer Practice 
1) EQUAL ACCESS 
You have a right to: 
Equal access to affordable and optimal available cancer care, 
including the right to a second opinion. 
Explanation 
European cancer patients should receive affordable, best available 
cancer care in their own country which is comparable to other high 
quality cancer services in Europe. The cornerstone of the European Code 
of Cancer Practice (ECCP) is the right of Europe’s cancer patients to have 
equal access to such cancer care. This means that you have the choice 
where to be treated and by whom, coupled with the right to obtain in-
formation about where best results are achieved. If you have a rare 
cancer (or are a paediatric patient), you also have the right to engage 
with the European Reference Networks (ERNs) relevant to your disease, 
Table 11 
Advice to employers from the Association of European Cancer Leagues (ECL) 
(from reference [216].  
Simple solutions can make big 
difference, such as:  
• Flexible and reduced working 
hours  
• Working from home  
• Additional work breaks  
• Time off for medical appointments  
• Sick and compassionate leave  
• Suspension of working alone  
• Alternative employment (change 
of post)  
• Reallocation and prioritisation of 
work duties  
• Temporary change of work area  
• Training for new skills  
• More convenient parking space  
• Mentoring colleagues and choosing a 
cancer issues supervisor  
• Avoiding excessive travel  
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if good clinical cancer practice for your disease is not available to you 
within your local area. Each cancer patient, with their family and carers, 
should have the opportunity to discuss with their healthcare pro-
fessionals whether the care that they will receive is the best available 
within their healthcare system and whether it is of the standard of good 
clinical cancer practice required by clinical guidelines. 
Currently, there are inequalities in access to best available cancer 
care, both within and between European countries and between 
different regions and communities within some countries. Many factors 
determine these inequalities, including the cost of care, the organisation 
of care, access to the right technologies, and the availability of skilled 
healthcare professionals to deliver the required treatment to the highest 
standard. In many countries, it is possible to access good clinical cancer 
practice which is in keeping with published guidelines based on the best 
available scientific and biomedical evidence. This may be provided close 
to a patient’s home or, when essential, by referral to a cancer centre 
which may be some distance away. Discussions between the patient and 
cancer professionals should identify the best available care options, so 
that the patient can make an informed choice. 
Patients should always have the right to a second opinion, in relation 
to their diagnosis and/or the treatment of their cancer and subsequent 
care. 
2) INFORMATION 
You have a right to: 
Information about your own disease and treatment from your med-
ical team and other reliable sources, including patient and professional 
organisations. 
Explanation 
European cancer patients are entitled to reliable, good quality, 
comprehensive information from their hospital about their disease, its 
treatment and the consequences of that treatment. Patients should be 
informed that they can ask questions about the diagnosis, treatment and 
the consequences of the disease and/or its treatment, as well as receiving 
information on nutrition, physical activity, psychological aspects, etc. 
The hospital should also refer the patient to patient organisations which 
can provide invaluable information and support at many levels. In some 
countries, patient organisations and hospitals organise information 
sessions for newly diagnosed patients, so that all their questions can be 
answered and ideas exchanged. 
Although patients are entitled to all relevant and comprehensive 
information if they so wish, how much information a patient wants 
about their cancer is up to that individual. Some patients prefer to be 
given a relatively small amount of basic information, leaving the com-
plexities to their healthcare professionals. However, increasingly most 
patients want to have a clear picture of their illness, how it can be 
treated and to receive sufficient information to be able to make informed 
decisions about their care and be reassured that the treatment they will 
receive will be the best available for them. 
Healthcare professionals will, in good modern clinical practice, 
explain to patients the nature of their illness, its extent and how that is 
measured, and the options for treatment and their likely outcomes. 
Explanations may come from the doctors or other members of the 
healthcare team. Cancer nurses will often have special communication 
skills and actively contribute to the consultation, either jointly with 
other healthcare professionals or individually and separately with the 
patients as required. The patient has the right to have someone of their 
choice with them during consultations and communications, often a 
close family member or friend. They have the right to ask for informa-
tion to be repeated in a meeting or in subsequent meetings and presented 
to them in language that is accessible and clear. Consultations may be 
recorded if a patient so wishes and with the consent of others present at 
the time, and the recordings used by the patient as a record and 
reminder of what was said. During the COVID-19 pandemic, many 
consultations have been performed online, to help ensure the safety of 
the cancer patient. Online advice on how to prepare for such consulta-
tions is available. It is important to ensure that patients are comfortable 
with this approach and that these consultations mirror, in as much as is 
possible, the face-to-face consultation. Patients should have the right to 
choose which type of consultation best suits their needs and situation. 
Information given at a consultation should be supported with good 
quality, relevant and clearly-written material provided by healthcare 
professionals, with appropriate explanations for the individual patient. 
Valuable written material is also available from patient advocacy or-
ganisations in many European countries. Guiding patients to reliable 
online material for subsequent reading is also important. Patients will 
often access information themselves online. Healthcare professionals 
should be prepared to answer questions about online findings and in 
particular relate this information to the patient’s individual cancer 
journey. Some websites will be highly evidence-based, while others will 
be more speculative. Engagement with healthcare professionals and 
patient advocacy organisations should help patients and their carers to 
successfully navigate online cancer advice. 
3) QUALITY OF CARE, EXPERTISE & BEST OUTCOMES 
You have a right to: 
Information about the quality and safety of care, the level of exper-
tise and the outcomes achieved for your type of cancer in the cancer care 
service where you are being treated. 
Explanation 
European cancer patients should be given access to information 
about the care provided and the outcomes achieved by their specific 
cancer healthcare team. This is essential to allow patients to take 
informed decisions about their treatment and where it is delivered. 
Different healthcare professionals deliver specific aspects of a pa-
tient’s diagnosis and care. While primary care and general practice 
healthcare professionals have skills that can help in identifying suspi-
cious symptoms, referring patients for a cancer diagnosis and supporting 
the individual through their healthcare journey, they will not have 
specialised cancer treatment expertise. Specialised cancer care should be 
given by a team of healthcare professionals with expertise in a specific 
cancer and its treatment in a hospital or a dedicated cancer centre. Pa-
tients have the right to know the level of expertise and experience of 
healthcare professionals and teams who will be looking after them. 
Therefore, they need access to information about the results their 
healthcare team have achieved, for their specific cancer, and how it 
compares to expected results from other hospitals or cancer centres. 
In order to achieve the best results for patients, their specialist care 
team must have substantial experience across a broad range of profes-
sional competencies. They must be well led and coordinated, have 
adequate resourcing and participate in training programmes to maintain 
and upgrade their skills. Professional organisations across Europe 
recommend the required level of activity and competency which is 
appropriate for a team (eg number of patients with that particular cancer 
type cared for by the team per year), to ensure the best results for pa-
tients. Application of the available European Cancer Organisation’s 
Essential Requirements for Quality Cancer Care can help support the 
delivery of best available care. 
Care teams should regularly audit their results and compare them to 
other similar teams in other institutions. However, comparisons be-
tween teams and their outcome results is not always straightforward, as 
different teams may be dealing with patients at different stages of their 
cancer and be using different treatments. Nonetheless, informative, 
careful comparisons are possible and this process ensures that the care 
team is continuously looking to improve and achieve the best outcomes 
for patients across all indicators of the quality of the care provided. This 
information should be made publicly available and accessible to patients 
to consider when they are making their decisions on treatment options 
and should be published by healthcare institutions, government de-
partments and/or professional organisations. 
4) SPECIALISED MULTIDISCIPLINARY CARE 
You have a right to: 
Receive care from a specialised multidisciplinary team, ideally as 
part of a cancer care network. 
M. Lawler et al.                                                                                                                                                                                                                                 
Journal of Cancer Policy 28 (2021) 100282
14
Explanation 
European cancer patients’ care should be organised so that the 
best decisions about choices of treatment are made, ensuring best 
available care is delivered in the most effective and timely way, as close 
to the patient’s home as is safely possible (link to the Health Systems and 
Treatment Optimisation Network). The two organisational structures 
recommended, the specialised multidisciplinary team (MDT) and the 
cancer network, are both well supported by evidence and experience. 
Specialised Multidisciplinary Team (MDT) 
A specialised MDT comprises all of the different healthcare pro-
fessionals, whose combined knowledge ensures that the best treatment 
options are discussed with the patient and that Shared Decision-Making 
(SDM) takes place. All treatment options should be considered and can 
be advocated by the relevant specialists; all relevant doctors, nurses and 
other cancer care professionals should be informed and kept up-to-date 
through all stages of the patient’s journey. 
Patients should be made aware of the MDT, its purpose, membership, 
when it meets, and that their case is being/has been discussed. They 
should receive the outcome of these discussions within a locally-agreed 
timeframe. A patient’s views, preferences and holistic needs should be 
presented to the MDT by a member of the team who has met the patient 
and discussed these aspects with her/him. Patients should be informed, 
in a consultation with the appropriate MDT member, of the results of 
MDT discussions, and its recommendations and the preferred options for 
treatment. Patients should receive information, consistent with their 
wishes, about their cancer, their diagnosis, and their treatment options, 
including therapies that may be available by referral to other MDTs in 
other cancer networks, ensuring a well-informed choice is made about 
their individual treatment and care. 
Cancer Networks 
It may not be possible to have all of the members of every MDT in 
every location where a cancer patient is diagnosed or treated. It may be 
necessary to centralise care by moving a diagnosed patient to a speci-
alised centre. This might happen, for example, if the patient has a rare/ 
very rare cancer and there is no expertise for treatment of this cancer in 
the patient’s closest institution. To ensure that care is integrated in a 
well-organised and streamlined way, the “Cancer Network” or the 
“Comprehensive Cancer Care Network” model has been developed. This 
involves different parts of the healthcare system including primary care, 
smaller community hospitals and large cancer centres working together, 
communicating effectively and ensuring that the patient’s travel to the 
specialised cancer centre is kept to the necessary minimum. In this 
approach, certain aspects of treatment are delivered in the specialised 
centre, while other aspects are safely provided closer to the patient’s 
home. Cancer care plans and long term survivorship plans should be 
shared between all parts of the network and regularly updated. 
5) SHARED DECISION-MAKING 
You have a right to: 
Participate in Shared Decision-Making with your healthcare team 
about all aspects of your treatment and care. 
Explanation 
European cancer patients should have a choice as to how decisions 
are taken about their cancer care and that choice should include Shared 
Decision-Making (SDM). Patients will have individual views about what 
is important in their life at the time of diagnosis and how they wish 
decisions to be made. While some patients may prefer for the doctor to 
take the decisions; most will prefer to take the decisions themselves. 
However, increasingly in good modern clinical cancer practice, a shared 
or collaborative approach is being employed, in which a doctor rec-
ommends treatment but takes account of the patient’s situation and 
views after careful discussion. 
SDM allows patients to fully inform themselves before making any 
choices about their treatment. Patients should have the possibility 
(either through the hospital or a patient advocacy organisation) to 
discuss with other patients who have gone through the same treatment 
successfully, to better understand the consequences of the treatment and 
how it will affect their quality-of-life. SDM also entails understanding 
the context in which the patient lives and identifying variations in the 
treatment plan, based on the patient’s specific situation. A fully 
informed patient can also have the option to not (or to no longer) receive 
specific anti-cancer treatment such as surgery, radiotherapy or 
chemotherapy. 
SDM requires good communications between the patient, the pa-
tient’s carers and family and the healthcare cancer professionals. The 
approach has to be tailored carefully to fit the needs and preferences of 
individual patients, whose views for the level of input into decisions will 
vary. The family/social/cultural situation may also impact on the indi-
vidual patient’s care and should be considered. There is no single “best 
approach”. Communicating choices about treatment must begin by 
clarifying the patient’s knowledge about cancer and its treatment and 
how much involvement in decision-making the patient wants, both at 
diagnosis and throughout their journey. It is also helpful to clarify what 
the patient considers to be a ‘good’ outcome from treatment. Family 
involvement is often helpful, although the views of family members may 
be different from the patient’s perspective. 
There is good evidence that clinical decisions should be informed by 
a consultation between the healthcare professional and the patient that 
involves clarification of the patient’s wishes and preferences, clear in-
formation about the purpose of treatment and the benefits/risks of the 
treatment. Patients want a good doctor-patient relationship: a doctor 
who is approachable, understanding and provides respectful care. In-
formation needs to be uncomplicated, specific, in lay language and as 
unambiguous as possible. Communication which strongly directs a pa-
tient to a single option can have negative consequences. Evidence sug-
gests that appropriately-judged SDM will improve patient outcomes and 
wellbeing and reduce the risk that patients will subsequently regret the 
decisions that have been taken. 
SDM is a key component of patient involvement and engagement, in 
which healthcare professionals encourage patients to influence how 
their own care and healthcare services are delivered. This relates to the 
wider concept of patient empowerment, in which patients may under-
take self-driven initiatives to influence how healthcare services can be 
improved. 
6) RESEARCH & INNOVATION 
You have a right to: 
Be informed about ongoing research relevant to you, and your ability 
and eligibility to participate in research. 
Explanation 
European cancer patients should be informed about any ongoing 
research and innovation in the cancer service which is providing their 
care, while recognising that most patients will receive standard-of-care 
treatment. Research and innovation have underpinned improvements in 
outcomes for cancer patients in recent decades, with long-term survival 
increasing to over 50 % of cancer patients in many European countries. 
Further improvements will depend substantially on appropriate imple-
mentation of research and innovation discoveries. If relevant clinical 
trials are available in another hospital which are not being offered in the 
patient’s hospital, patients should have the option to change hospital in 
order to participate. Patients should have the right to participate (or 
refuse to participate) in clinical research. The informed decision that 
they take, after careful discussion with the clinical investigators, is a 
personal one. Patients must also be assured by the clinical team that a 
decision to not participate in clinical research or to withdraw from a 
research study, will not adversely affect their care. 
Clinical cancer research provides the evidence which ensures pa-
tients receive the best available care. It improves healthcare delivery, 
leading to better outcomes and improved quality-of-life for patients. 
Research which links the laboratory to the clinic is an essential 
component of a comprehensive cancer control strategy. There is evi-
dence that research-active hospitals provide better care, achieve higher 
levels of patient satisfaction and deliver improved survival for patients 
compared to hospitals that are not active in research. 
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There are many kinds of clinical research. In some, researchers will 
ask for a patient’s consent just to collect information about them for 
research purposes. In other research, the patient’s diagnostic tests and 
treatments may be directly determined by clinical research protocols, 
but only after the patient has been fully informed and has given their 
consent. Patients may be asked to consider whether they are prepared to 
receive a new experimental treatment, in addition to or after they have 
received the standard care. They may also be invited to join in a rand-
omised controlled trial (RCT). Here, one group of patients receive the 
standard-of-care treatment, while a second group of patients are allo-
cated to a different treatment that is under trial. The process of alloca-
tion to the groups is called randomisation and it ensures that the two 
groups are truly comparable so that the results achieved are robust. At 
the end of the trial, results for the two groups of patients are compared 
so that the better treatment can be identified with confidence and used 
in future to improve cancer care. 
Clinical research is highly regulated and carefully monitored to 
ensure that it is properly conducted, and that patient participation is 
properly sought with written informed consent and appropriate patient 
information. Very importantly, it is strictly monitored to ensure the 
maximum possible safety for patients who choose to participate in 
research studies. 
7) QUALITY-OF- LIFE 
You have a right to: 
Discuss with your healthcare team your priorities and preferences to 
achieve the best possible quality-of-life. 
Explanation 
European cancer patients should expect to live as normally as 
possible with the optimum quality-of-life following their diagnosis, 
during treatment and through survivorship. Patients must be thoroughly 
informed on both medical and non-medical aspects of care and survi-
vorship. Patients and their healthcare professionals must work together 
to preserve quality-of-life, while maximising chances of survival or cure. 
This will mean a focus not only on the patient’s survival, their physical 
symptoms, test findings, the technological aspects of their care and the 
side-effects of treatment, but also the impact on daily functioning and 
wellbeing, relationship problems, work-related issues, financial hard-
ship and social isolation. This may be particularly important and chal-
lenging when cancer treatments are associated with significant toxicity 
in the short, medium or long term. Striking the right balance in terms of 
survival and quality-of-life is particularly challenging where this risk of 
toxicity is associated with treatments that deliver only modest or un-
certain improvements in the person’s survival. Maximising the quality of 
patient’s lives is now considered a hallmark of successful cancer care. 
Referring patients to patient advocacy groups will provide additional 
support, particularly on the issues that patients specifically find 
challenging. 
Methods for measuring quality-of-life are now increasingly used in 
cancer care and clinical research, in particular Patient Reported 
Outcome Measures (PROMs). PROMs are defined as ‘any report of the 
status of a patient’s health condition that comes directly from the pa-
tient, without interpretation of the patient’s response by a clinician or 
anyone else.’ PROMs provide a formal measurement of the patient’s 
experience of symptoms, treatment, daily functioning and health-related 
quality-of-life (HRQOL), and they reveal important patient-focussed 
information on quality of care. PROMs can be measured using care-
fully developed and validated questionnaires (sometimes called “tools” 
or “instruments”) in clinical practice and in clinical trials. PROMs are 
developed jointly by patients and professionals and include questions 
derived from patients’ concerns and experience. 
Psychological distress is commonly experienced by cancer patients 
during their treatment and thereafter and is a major factor in poor 
quality-of-life, reflected in challenges such as self-esteem, changing roles 
of couples in relationships, social isolation etc. In a minority of patients, 
it may even precipitate a psychiatric disorder such as clinical depression. 
Healthcare services should provide psychological support, both to detect 
and manage such changes in the person’s wellbeing. During and after 
their treatment, many cancer patients may experience social difficulties 
in all domains of life in their homes, in their interaction with healthcare 
services, with personal finance, with family relationships and in housing 
and mobility. Cancer patients should expect that healthcare pro-
fessionals and healthcare services are aware of these challenges and are 
able to advise on and mobilise the appropriate assessments and mea-
surements, advice and support to reduce social and financial difficulties. 
8) INTEGRATED SUPPORTIVE & PALLIATIVE CARE 
You have a right to: 
Receive optimal supportive and palliative care, as relevant, during 
any part of your cancer journey. 
Explanation 
European cancer patients should have access to supportive and 
palliative care at any point of their cancer journey, from diagnosis, as 
survivors or in end-of-life care. Most cancer patients require supportive 
and palliative care at some stage of their care pathway. This may be 
particularly true of patients whose disease will prove ultimately not to 
be curable, but is also relevant for many patients who, sometimes 
following complex and difficult treatment programmes, achieve long 
term survival and good quality-of-life. As a patient, you have the right 
not to receive specific anti-cancer treatment such as surgery, radio-
therapy or chemotherapy, but to choose supportive and palliative care to 
alleviate your symptoms. You have the right to make your own end-of- 
life decisions and for your choices to be respected as far as they can be 
within the current laws of the country within which you are receiving 
your care. You may choose to make decisions about your care in advance 
of the immediate need for them so that your wishes are clear for the 
future. 
Supportive and palliative care can be provided from many sources 
within healthcare, in the community, in hospitals or hospices, from 
patients’ families and carers and from patient organisations. It may be 
provided by the cancer care team and by full-time palliative care pro-
fessionals. Expert supportive care is often to be found in specialised 
palliative care units, where skills in the patient’s psychosocial support 
and symptom relief complement the complex often highly technical 
treatment options that are tailored to maximise quality-of-life. 
There is evidence that involving supportive and palliative care early 
in the management of patients with cancer can improve their quality-of- 
life and in some circumstances improve their survival. Providing pa-
tients with good communication and supportive and palliative care may 
improve wellbeing and outcomes, reduce hospital admissions and length 
of stay and lower overall healthcare costs. 
In most European countries, palliative care is a separate clinical 
discipline from oncology and the teams providing palliative care are 
responsible for many patients, not only those with cancer. However, the 
support of cancer patients is a large part of palliative care and the 
multidisciplinary palliative care teams have substantial expertise in the 
support of cancer patients and the management of their symptoms at all 
stages of their cancer pathway. Close working between cancer care and 
palliative care teams is a feature of good clinical cancer practice. 
9) SURVIVORSHIP & REHABILITATION 
You have a right to: 
Receive and discuss with your care team a clear, managed and 
achievable plan for your survivorship and rehabilitation. 
Explanation 
European cancer patients’ care should be supported in their needs 
as a cancer survivor. In response to the growing number of people sur-
viving cancer in Europe, there has been increasing focus on the quality 
of survival. In this setting, “survivorship” has various definitions. It can 
include anyone diagnosed with cancer and include their entire cancer 
journey. More often, the focus will be on patients’ survival from the 
period of time after they complete their active treatment. However, 
preparations to support survivorship can begin before active treatment 
is completed. A number of patient advocacy organisations have exten-
sive experience in this area and patients should be referred to these 
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organisations for information on support groups and guidelines, 
including on work- and finance-related issues. 
Cancer and its treatment can have a considerable and long-term 
impact on everyday life. Some cancer survivors may face a range of 
challenges including physical problems, poorer quality-of-life, psycho-
logical distress, sexual problems, problems with social relationships and 
financial concerns. Some consequences may emerge five or ten years 
after treatment (late effects) and can have a significant impact. For 
example, cancer patients may be at greater risk of a second cancer; some 
chemotherapy can increase the risk of heart disease, and long-term 
hormone therapy can sometimes be related to development of 
osteoporosis. 
Supporting cancer survivors includes providing psychosocial aspects 
of support, such as coping with disruption to one’s life, managing the 
consequences of treatment, living with uncertainty and lifestyle 
changes. Being a cancer survivor may disrupt one’s social and sexual 
roles and identity. Patient advocacy organisations can offer significant 
help to support the cancer survivor. 
High-quality cancer care should include an active approach to the 
challenges that patients face as cancer survivors. Every patient should be 
given a survivorship cancer plan, prepared for them in consultation 
with their cancer care professionals and fully explained. Patient advo-
cacy organisations have a lot of experience in the practical issues that 
arise (eg relating to work, travel, leisure activities etc) and should be 
consulted. It is important that the cancer professionals and patients 
together identify and discuss any particular risks that the individual may 
have; specific approaches can then be taken to reduce those risks. These 
may include lifestyle changes such as giving up smoking, maintaining 
exercise, ensuring good nutrition and a healthy body weight. They may 
also involve medical follow-up measures including screening for the late 
complications of cancer and its treatment. Supportive care should be 
available for those patients who experience psychological distress, sex-
ual or social problems as well as for those who have physical problems or 
late complications of the treatment or the disease. Survivorship care 
plans should be regularly reviewed and updated to reflect changes in 
circumstances and evolving life goals. 
10) REINTEGRATION 
You have a right to: 
Be fully reintegrated into society and protected from cancer-related 
stigma and discrimination, so that, in so far as is possible, you can re-
turn to work and a normal life. 
Explanation 
European cancer patients should be able to reintegrate into society 
to the fullest extent possible, regardless of many factors including age, 
place of residence, sexual preference, gender, ethnicity, cognitive abil-
ity, religion, psychological state, education and job, and socio-economic 
class. However, increasing numbers of cancer survivors are facing 
challenges in some or all of these areas as they reintegrate into society. 
Work-associated stigma may include loss of employment, lack of op-
portunities for promotion or international work-related travel. Survivors 
should be able to obtain appropriate support and advice to help them 
with the process of reintegration, to sustain their quality-of-life, to 
ensure their ability to earn a living and to have an active and fulfilling 
social life and to contribute to society. These supports and advice should 
be signposted at the earliest possible stage by the cancer care team; some 
may be delivered by the cancer care teams themselves while others may 
be provided through patient advocacy groups (who will have specific 
expertise in advising survivors on social legislation, talking to em-
ployers, etc), community groups and government agencies or employers. 
The diagnosis of cancer may disrupt family and social life and may 
lead to substantial absence from work through sickness. Cancer survi-
vors may have long-term symptoms as a consequence of their disease or 
its treatment. Fatigue, emotional and mental health problems, persistent 
symptoms or reduced attention and memory can significantly diminish a 
cancer survivor’s working abilities, usually in the short term but occa-
sionally in the longer term. There is an increased risk of unemployment 
among cancer survivors, perhaps 1.4 times higher than the general 
population of similar age. 
Interventions that can help with reintegration into the workplace 
and other aspects of life can include workplace arrangements to allow 
flexible working or reduced working hours, modifications of duties or 
the provision of assistance in a working role, and psychological and 
educational interventions. These may sometimes be provided by tele-
phone or websites or through patient advocacy groups specialising in 
this type of support. Employers, however well motivated, may need 
some help to design interventions that support cancer patients in 
returning to the workplace. Healthcare teams and some patient advo-
cacy organisations can help to guide back-to–work strategies, including 
making agreements with the employer at the time of diagnosis and 
discussion with Human Resource departments on return to work. Some 
countries offer flexible reintegration schemes through social services. At 
the moment, provision of support for cancer patients returning to the 
workplace varies substantially across Europe. Cancer patients should 
also have the Right to be Forgotten, so that a previous diagnosis and 
treatment does not stigmatise cancer survivors in any way on their 
journey to return to normal living. 
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[45] R. Althin, R. Färe, K. Gralen, et al., Efficiency and productivity of cancer care in 
Europe, J. Cancer Policy 21 (2019) 100–194. 
[46] G. Carioli, P. Bertuccio, P. Bofetta, et al., European cancer mortality predictions 
for the year 2020 with a focus on Prostate cancer, Ann. Oncol. 31 (2020) 
650–658. 
[47] M. Lawler, P. Selby, M.S. Aapro, et al., Ageism in cancer care, BMJ 348 (2014) 
1614. 
[48] A. Ring, D. Harari, T. Kalsi, J. Mansi, P. Selby, Problem Solving in Older Cancer 
Patients, Clinical Publishing, Oxford, 2016. 
[49] Y. Lievens, H. De Schutter, K. Stellamans, et al., Belgian College for Physicians in 
Radiation Oncology. Radiotherapy access in Belgium: how far are we from 
evidence-based utilisation? Eur. J. Cancer 84 (2017) 102–113. 
[50] European Society for Medical Oncology, 2021. https://www.esmo.org 
/guidelines. 
[51] European Cancer Organisation, 2021. https://www.europeancancer.org. 
[52] European Cancer Patient Coalition, 2021. https://ecpc.org/news-events/new-ec 
pc-website/. 
[53] European School of Oncology, 2021. https://www.eso.net/. 
[54] Association of European Cancer Leagues, 2021. https://www.europeancancerlea 
gues.org/. 
[55] European Society of Surgical Oncology, 2021. https://www.essoweb.org. 
[56] European Society for Radiotherapy and Oncology, 2021. https://www.estro.org. 
[57] European Alliance for Personalised Medicine, 2021. https://www.euapm.eu. 
[58] European Public Health Association, 2021. https://eupha.org. 
[59] European Oncology Nursing Society, 2021. https://www.cancernurse.eu. 
[60] European Society of Oncology Pharmacy, 2021. https://esop.li. 
[61] European Society of Radiology, 2021. https://www.myesr.org. 
[62] European Society of Pathology, 2021. https://www.esp-pathology.org. 
[63] European Organisation for Research and Treatment of Cancer, 2021. htt 
ps://www.eortc.org. 
[64] European Society for Paediatric Oncology, 2021. https://siope.eu. 
[65] International Psycho-oncology Society, 2021. https://www.ipos-society.or. 
[66] International Society of Geriatric Oncology, 2021. https://www.siog.or. 
[67] European Association for Palliative Care, 2021. https://www.eapcnet.eu. 
[68] Working Group on Cancer in Adolescents and Young Adults (AYA), 2021. https:// 
www.esmo.org/about-esmo/organisational-structure/educational-committee/a 
dolescents-and-young-adults-working-group. 
[69] The European Academy of Cancer Sciences, 2021. https://www.europeancance 
racademy.eu/. 
[70] E. Abrahams, M. Foti, M.A. Kean, Accelerating the delivery of patient-centred, 
high-quality cancer care, Clin. Cancer Res. 21 (2015) 2263–2267. 
[71] The Expert Advisory Group on Cancer to the Chief Medical Officers of England 
and Wales. A Policy Framework for Commissioning Cancer Services: a Report by 
the Expert Advisory Group on Cancer to the Chief Medical Officers of England and 




[72] UICC - CICA, Guidelines for Developing a Comprehensive Cancer Centre, UICC, 
Geneva, 1978. 
[73] National Institutes of Health (NIH), Cancer Center Support Grants (CCSGs) for 
NCI-designated Cancer Centers, NIH Funding Opportunities and Notices, National 
Cancer Institute (NCI), 2020 (accessed on 24 November 2020), https://grants.nih 
.gov/grants/guide/pa-files/PAR-20-043.html. 
[74] T. Philip, S. Oberst, C. Lombardo, OECI Accreditation and Designation User 
Manual, Appendix 2, Chapters 1-9. (Accessed 16 Jan 2021, https://www.oeci. 
eu/Accreditation/Attachments/OECI_AD_MANUAL_3_2019.pdf. 
[75] Organisation of European Cancer Institutes, 2021. https://www.oeci.eu. 
[76] S. Oberst, W. van Harten, G. Sæter, et al., 100 European core quality standards for 
cancer care and research centres, Lancet Oncol. 21 (8) (2020) 1009–1011. 
[77] E.A. Halm, C. Lee, M.R. Chassin, Is volume related to outcome in health care? A 
systematic review and methodologic critique of the literature, Ann. Intern. Med. 
137 (6) (2002) 511–520. 
[78] R.E. Glasgow, S.J. Mulvihill, Hospital volume influences outcome in patients 
undergoing pancreatic resection for cancer, West. J. Med. 165 (5) (1996) 
294–300. 
[79] C.B. Begg, L.D. Cramer, W.J. Hoskins, M.F. Brennan, Impact of hospital volume 
on operative mortality for major cancer surgery, JAMA 280 (20) (1998) 
1747–1751. 
[80] M.C. Cheung, K. Hamilton, R. Sherman, et al., Impact of teaching facility status 
and high-volume centers on outcomes for lung cancer resection: an examination 
of 13,469 surgical patients, Ann. Surg. Oncol. 16 (1) (2009) 3–13. 
[81] S. Wang, S. Lai, M.S. von Itzstein, et al., Type and case volume of health care 
facility influences survival and surgery selection in cases with early-stage non- 
small cell lung cancer, Cancer 125 (23) (2019) 4252–4259. 
[82] Y. Freifeld, S.L. Woldu, N. Singla, et al., Impact of hospital case volume on 
outcomes following radical nephrectomy and inferior Vena cava thrombectomy, 
Eur Urol Oncol 2 (6) (2019) 691–698. 
[83] S.J. Torabi, L. Benchetrit, P. Kuo Yu, et al., Prognostic case volume thresholds in 
patients with head and neck squamous cell carcinoma, JAMA Otolaryngol. Head 
Neck Surg. 145 (8) (2019) 708–715. 
[84] D. Avdic, P. Lundborg, J. Vikström, Estimating returns to hospital volume: 
evidence from advanced cancer surgery, J. Health Econ. 63 (2019) 81–99. 
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[217] Prokupkova A., Rosàs C., Rommel W. https://www.europeancancerleagues.org/ 
wp-content/uploads/2018/05/Return-to-Work-presentation-for-employers_2018. 
pdf. 
[218] M. Lawler, K. Oliver, S. Gijssels, et al., Implementing the european code of Cancer 
practice to improve Europe’s Cancer outcomes, Europe. J. Oncol. Haematol. 
(2021). Submitted. 
M. Lawler et al.                                                                                                                                                                                                                                 
